The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

Dosimetry for personalized radiopharmaceutical therapy has gained considerable attention. Many methods, tools, and workflows have been developed to estimate absorbed dose (AD). However, ...

Cardiac allograft vasculopathy (CAV) causes impaired blood flow in both epicardial vessels and microvasculature and remains a leading cause of posttransplant morbidity and mortality. This study ...

Fibroblast activation protein (FAP) has become an attractive target for diagnosis and therapy, and a series of FAP inhibitor (FAPI) based radiotracers have been developed and performed excellent ...

We propose strongly unrealistic data augmentation to improve the robustness of convolutional neural networks (CNNs) for automatic classification of dopamine transporter SPECT against the variability ...

In the May 2024 supplement issue of The Journal of Nuclear Medicine, an insightful article by Chen et al. was published: “Advancing Global Nuclear Medicine: The Role and Future Contributions of China” ...

The PSMA-PET Registry for Recurrent Prostate Cancer study was initiated in Ontario, Canada, to provide access to and characterize the performance of 18F-prostate-specific membrane antigen (PSMA) ...

Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals ...

One important aspect of radiopharmaceutical therapy (RPT) that sets it apart from virtually all other oncologic therapeutic approaches is the ability to noninvasively image and verify the existence of ...